Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.
The mRNA Vaccines Market grew from USD 9.32 billion in 2024 to USD 10.40 billion in 2025. It is expected to continue growing at a CAGR of 11.86%, reaching USD 18.28 billion by 2030.
The mRNA vaccine landscape has experienced transformative shifts that underscore the evolution of medical innovation and technological integration. In recent years, unprecedented advances in formulation techniques and delivery systems have redefined the boundaries of vaccine development. Enhanced methods in nucleoside modification, lipid nanoparticle encapsulation, and self-amplifying mRNA platforms mean that vaccines can be deployed more precisely and at greater speeds than previously imagined.
These transformative shifts are not limited solely to the technology itself; the regulatory environment, industrial collaborations, and public-private partnerships have advanced in tandem with scientific breakthroughs. A reformed regulatory outlook coupled with robust funding models has helped streamline clinical trials and expedite the approval process. Emerging trends indicate a movement away from traditional vaccine platforms toward more dynamic and responsive mRNA solutions that cater to rapidly changing health scenarios.
As a result, industry participants are better positioned to anticipate market needs and harness the potential of mRNA. The emphasis on scalability and adaptability is evident in the way manufacturers and innovators are rethinking production methodologies. By investing in innovative manufacturing processes and reimagining the vaccine life cycle, key players are not only responding to current challenges but are also preparing to meet future public health demands. This evolution is transforming market dynamics while setting a new standard for what is achievable with modern vaccine technology.
Global Regional Insights and Market Opportunities
The global reach of mRNA vaccine technology offers a range of regional insights that are especially pertinent in today's connected world. In the Americas, strong investment in biotechnology research and development, coupled with robust healthcare infrastructure, has created fertile ground for mRNA innovations. North American markets, in particular, have been quick to adopt the latest vaccine technologies, leading to rapid integration into public health strategies.
Europe, Middle East & Africa showcase a mixed landscape where advanced healthcare systems in parts of Europe drive market maturity, while emerging markets in the Middle East and Africa offer significant potential through rapidly evolving regulatory frameworks and government incentives. These regions demonstrate a balanced blend of established research excellence and untapped market potential.
Meanwhile, the Asia-Pacific region stands out with its diverse market dynamics. The confluence of high population density, increasing bio-tech investments, and proactive government policies has fostered a thriving environment for mRNA vaccine development. The interplay between tradition and modernity in healthcare delivery, combined with improvements in regional manufacturing capacities, positions the Asia-Pacific as a vital market for future growth. These regional insights illustrate the broad geographic impact of mRNA vaccine innovation and underscore the importance of a tailored approach to market strategies in each region.
Competitive Landscape
The report delves into recent significant developments in the mRNA Vaccines Market, highlighting leading vendors and their innovative profiles. These include:
- Acuitas Therapeutics Inc.
- Alnylam Pharmaceuticals Inc.
- Arcturus Therapeutics Holdings Inc.
- AstraZeneca PLC
- Bavarian Nordic AS
- BioNTech SE
- Chongqing Zhifei Biological Products Co. Ltd.
- CureVac N.V.
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- Ethris GmbH
- GlaxoSmithKline PLC
- Inovio Pharmaceuticals Inc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Moderna Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Roche Holding AG
- Sanofi SA
- Sinovac Biotech Ltd.
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific Inc.
- Vertex Pharmaceuticals Incorporated
Strategic Recommendations for Market Advancement
Industry leaders are encouraged to prioritize adaptive strategies and proactive investments in advanced manufacturing techniques to maintain competitive advantage. It is imperative for decision-makers to anticipate regulatory trends and invest in agile production methods, such as cell-free synthesis and in vitro transcription, to reduce time-to-market for new vaccine candidates. Strengthening public-private partnerships can facilitate innovation and accelerate the development of next-generation mRNA platforms. Collaborative ventures that bridge research institutions and industry leaders will be essential to harness the full potential of mRNA technology.
Moreover, leveraging data-driven insights into market segmentation and regional dynamics can inform targeted product launch strategies. By closely monitoring end-user requirements and distribution channel efficiencies, market stakeholders can better navigate competitive pressures and ensure sustainable growth in a dynamic global landscape.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 199 |
| Forecast Period | 2025-2030 |
| Estimated Market Value (USD) in 2025 | $10.4 Billion |
| Forecasted Market Value (USD) by 2030 | $18.28 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
Key Topics Covered
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of infectious diseases and emerging viral outbreaks spur demand for mRNA vaccines
5.1.1.2. Expansion of mRNA vaccine in animal health sectors is set to market potential
5.1.1.3. Public and governmental support for pandemic preparedness pushes forward mRNA vaccine initiatives
5.1.2. Restraints
5.1.2.1. Public skepticism towards new vaccine technologies, by misinformation, could impede uptake.
5.1.3. Opportunities
5.1.3.1. Developing educational campaigns and public-private partnerships to promote mRNA vaccine benefits and safety
5.1.3.2. Governmental and private funding to advance mRNA vaccine research and development
5.1.4. Challenges
5.1.4.1. Understanding the complex regulatory frameworks for mRNA vaccine approvals
5.2. Market Segmentation Analysis
5.2.1. Technology Type: Growing use of lipid nanoparticle platforms for their ability to deliver mRNA into cells effectively
5.2.2. Distribution Channel: Adoption of hospital pharmacies for storing and timely administering mRNA vaccines
5.3. Porter's Five Forces Analysis
5.4. PESTLE Analysis
6. mRNA Vaccines Market, by Technology Type
6.1. Introduction
6.2. Lipid Nanoparticle (LNP) Platforms
6.3. Naked mRNA Technologies
6.3.1. Peptide-Based Carriers
6.3.2. Polymeric Nanoparticles
6.4. Nucleoside-Modified mRNA Technologies
6.5. Self-Amplifying mRNA Platforms
7. mRNA Vaccines Market, by Route of Administration
7.1. Introduction
7.2. Inhalable mRNA Vaccines
7.3. Injectable mRNA Vaccines
7.4. Oral Delivery System
8. mRNA Vaccines Market, by Manufacturing Process
8.1. Introduction
8.2. Cell-Free Synthesis
8.3. In Vitro Transcription
9. mRNA Vaccines Market, by Vaccine Classification
9.1. Introduction
9.2. Preventive Vaccines
9.3. Therapeutic Vaccines
10. mRNA Vaccines Market, by Application Areas
10.1. Introduction
10.2. Cardiovascular Disorders
10.3. Genetic Disorders
10.3.1. Cystic Fibrosis Treatments
10.3.2. Sickle Cell Disease mRNA Approaches
10.4. Infectious Diseases
10.4.1. COVID-19 Vaccines
10.4.2. Influenza mRNA Vaccines
10.5. Oncology
11. mRNA Vaccines Market, by End-User
11.1. Introduction
11.2. Biotechnology Firms
11.3. Contract Research Organizations
11.4. Pharmaceutical Companies
11.5. Research Institutes
12. mRNA Vaccines Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Retail Pharmacies
13. Americas mRNA Vaccines Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific mRNA Vaccines Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa mRNA Vaccines Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Scenario Analysis
16.3.1. Pfizer and BioNTech secure FDA approval for tailored Omicron KP.2 COVID-19 vaccine
16.3.2. BioNTech and CEPI joined hands to enhance Africa's mRNA vaccine landscape with innovative research and local manufacturing
16.3.3. Moderna revealed late-stage trial advancements with progress in the evolution of mRNA vaccine technology
16.4. Strategy Analysis & Recommendations
For more information about this report visit https://www.researchandmarkets.com/r/azzxne
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
